




 Community-acquired pneumonia (CAP) is the most common infectious cause of hospitalization in the 
United States. 1 CAP is associated with high short- and 
long-term mortality and many morbid sequelae that 
may last for several years. 2-4 However, it is not known 
whether the long-term risk of pneumonia can be pre-
dicted in community-dwelling individuals, similar to 
cardiovascular disease and cancer. 5,6 
 Individuals who are older than 65 years or have a 
chronic health condition are considered to be at high 
 Background:  Preventing pneumonia requires better understanding of incidence, mortality, and 
long-term clinical and biologic risk factors, particularly in younger individuals. 
 Methods:  This was a cohort study in three population-based cohorts of community-dwelling indi-
viduals. A derivation cohort (n  5 16,260) was used to determine incidence and survival and develop 
a risk prediction model. The prediction model was validated in two cohorts (n  5 8,495). The primary 
outcome was 10-year risk of pneumonia hospitalization. 
 Results:  The crude and age-adjusted incidences of pneumonia were 6.71 and 9.43 cases/1,000 
person-years (10-year risk was 6.15%). The 30-day and 1-year mortality were 16.5% and 31.5%. 
Although age was the most important risk factor (range of crude incidence rates, 1.69-39.13 cases/1,000 
person-years for each 5-year increment from 45-85 years), 38% of pneumonia cases occurred in 
adults  , 65 years of age. The 30-day and 1-year mortality were 12.5% and 25.7% in those  , 65 years 
of age. Although most comorbidities were associated with higher risk of pneumonia, reduced 
lung function was the most important risk factor (relative risk  5 6.61 for severe reduction based 
on FEV 1 by spirometry). A clinical risk prediction model based on age, smoking, and lung function 
predicted 10-year risk (area under curve [AUC]  5 0.77 and Hosmer-Lemeshow [HL] C statistic  5 0.12). 
Model discrimination and calibration were similar in the internal validation cohort (AUC  5 0.77; 
HL C statistic, 0.65) but lower in the external validation cohort (AUC  5 0.62; HL C statistic, 0.45). 
The model also calibrated well in blacks and younger adults. C-reactive protein and IL-6 were 
associated with higher pneumonia risk but did not improve model performance. 
 Conclusions:  Pneumonia hospitalization is common and associated with high mortality, even in 
younger healthy adults. Long-term risk of pneumonia can be predicted in community-dwelling 
adults with a simple clinical risk prediction model.   CHEST 2013; 144(3):1008–1017 
 Abbreviations:  ARIC  5 Atherosclerosis Risk in Communities; AUC  5 area under curve; CAP  5 community-acquired 
pneumonia; CDC  5 Centers for Disease Control and Prevention; CHS  5 Cardiovascular Health Study; CRP  5 C-reactive 
protein; Health ABC  5 Health, Aging, and Body Composition; HL  5 Hosmer-Lemeshow; ICD-9  5  International Classifi cation 
of Diseases, Ninth Revision ; IDI  5 integrated discrimination improvement; IRB  5 institutional review board; NRI  5 net 
reclassifi cation improvement; RR  5 relative risk 
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risk for pneumonia. 7 These fi ndings are based on prior 
studies that were conducted in small cohorts, which 
included few young individuals and had limited ethnic 
diversity and short follow-up, 8-12 or in administrative 
datasets, which lacked accurate information about clin-
ical risk factors. 13 Whether the long-term risk of pneu-
monia is similar across all older adults and for different 
chronic health conditions is not known. Animal and 
small human studies suggest that circulating biomarker 
levels may be associated with higher risk of pneu-
monia, 14 but their role has not been assessed system-
atically in a large population-based study. 
 Understanding the role of individual clinical and 
biologic risk factors and predicting the long-term risk 
of pneumonia in an individual is important to target 
preventive strategies that have adverse effects and 
are expensive, such as statins. 15-23 Clinical trials to test 
these interventions will have to be conducted in high-
risk individuals fi rst, and, if effective, these interven-
tions could be targeted to broader populations based 
on the risk-benefi t profi le. However, there is no tool 
to predict risk of pneumonia, similar to risk-prediction 
tools for cardiovascular disease and cancer. 5,6 Current 
guidelines for pneumococcal vaccination target a very 
broad population and cannot be used to test inter-
ventions that are expensive or have adverse events. 
We, therefore, sought to determine the incidence and 
understand the role of clinical and biologic factors that 
increase the 10-year risk of pneumonia hospitaliza-
tions. We developed and validated a risk prediction 
model in  . 24,000 participants from three nationally 
representative cohorts that span middle and older 
age. 
 Materials and Methods 
 Subjects and Design 
 See e-Appendix 1 for details. We used a cohort design, using 
three population-based prospective studies. 24-26 We pooled data 
from the Atherosclerosis Risk in Communities (ARIC) (n  5 15,792) 
and Cardiovascular Health Study (CHS) (n  5 5,888) cohorts because 
these cohorts included community-dwelling participants without 
disability and had nonoverlapping age ranges (ARIC, 45-64 years; 
CHS,  . 65 years), they were recruited during the same time period 
(ARIC, 1987-1989; CHS, 1989-1990) and from similar geographic 
areas, they used similar study procedures, and they had similar 
follow-up ( . 10 years). We randomly split the pooled data into 
three quarters to determine the incidence, understand the role of 
individual risk factors, and integrate these risk factors to develop 
a risk prediction model (derivation cohort). The remaining one-
quarter of the pooled data were used for internal validation of the 
model (internal validation cohort). For external validation, we used 
the Health, Aging, and Body Composition (Health ABC) (n  5 3,075) 
study, a more contemporary cohort recruited in 1997-1998 with 
10-year follow-up data. 
 The institutional review boards (IRBs) at each site approved all 
three studies (ARIC IRB approval #11-0734 at University of North 
Carolina, and CHS IRB approval #950706 and Health ABC IRB 
approval # 960212 at University of Pittsburgh). Participants gave 
written informed consent. 
 Outcomes 
 The primary outcome was hospitalization with pneumonia within 
a 10-year period. We used a combination of  International Classi-
fi cation of Diseases, Ninth Revision (ICD-9) codes with chart 
review and physician adjudication. For ARIC and CHS, we used 
ICD-9 codes 480 to 487 in the fi rst fi ve discharge diagnoses fi elds 
to identify hospitalizations with pneumonia. We also identifi ed 
hospitalizations for bacterial pneumonia by including hospitaliza-
tions with ICD-9 codes that are commonly used for bacterial pneu-
monia (481, 482, 485, and 486) and are listed only in the primary 
diagnosis fi eld. In Health ABC, physicians adjudicated hospitali-
zations for pneumonia after chart review. 
 The use of 480 to 487 ICD-9 codes to identify pneumonia hos-
pitalizations has been validated in prior studies, 13,27,28 and we also 
reviewed 158 charts to assess accuracy of these ICD-9 codes in 
our cohorts. For ICD-9 codes used for bacterial pneumonia, a 
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clinical diagnosis of CAP was recorded in 94% of cases, and a 
radiologic diagnosis was recorded in 96% of cases. For ICD-9 
codes 480 to 487 in the fi rst fi ve discharge diagnoses fi elds, a clinical 
and radiologic diagnosis was recorded in 89% and 88% of cases. 
For cases in which a diagnosis of pneumonia was recorded in sec-
ond through fi fth diagnoses fi elds, pneumonia was the primary 
reason for hospitalization in 65% of cases. 
 Clinical Risk Factors 
 Clinical risk factors for pneumonia were chosen based on liter-
ature review and our prior work in CHS and Health ABC. 8-12,24 We 
assessed the role of the following clinical risk factors at baseline: 
demographic characteristics (age, sex, and race), BMI, health behav-
iors (smoking and alcohol abuse), lung function (FEV 1 based on 
spirometry), and chronic diseases (heart failure, coronary heart 
disease, diabetes, and chronic kidney disease). 
 Infl ammatory Biomarkers 
 See e-Appendix 1 for details. We sought to determine whether 
specifi c infl ammatory biomarkers increased risk and improved the 
performance of the clinical risk prediction model. Higher proin-
fl ammatory cytokines increase risk of pneumococcal pneumonia 
in animal studies. 14,24,29 We examined circulating C-reactive protein 
(CRP) level because it is an important opsonin and may protect 
against pneumococcal pneumonia. 30,31 We examined IL-6 level 
because it may be a marker for increased cellular senescence 32 
and may increase adherence of pneumococci to cells in the lung. 14,29 
CRP levels were available in all three cohorts at different time 
points, but IL-6 levels were available in Health ABC only. 
 Statistical Analyses 
 We fi rst determined frequency, crude and age-adjusted inci-
dence rates of pneumonia by age groups, and mortality after pneu-
monia. We conducted univariate comparisons to determine relative 
risk (RR) for each risk factor. We then developed a simple and 
parsimonious clinical risk prediction model to predict 10-year risk 
of pneumonia hospitalization in the derivation cohort using logis-
tic regression. We assessed the discriminative ability of each vari-
able by calculating the area under curve (AUC). We sequentially 
added variables to age, which had the highest AUC, calculated 
AUC and net reclassifi cation improvement (NRI) for each combi-
nation, and chose the combination that had the highest AUC and 
NRI. 33 We assessed calibration of the model by comparing the 
predicted and observed risk and calculating the Hosmer-Lemeshow 
(HL) C statistic. We validated the clinical model in the internal 
and external validation cohorts. 
 We conducted four sensitivity analyses: (1) compared estimates 
for different sets of ICD-9 codes due to differing sensitivity and 
specifi city to determine hospitalizations for pneumonia; (2) com-
pared estimates from logistic regression (RR) and Cox propor-
tional hazards (hazard ratio) models, because hazard ratios account 
for censoring due to mortality; (3) assessed model calibration in 
blacks and those  , 65 years of age to determine generalizability; 
and (4) evaluated ability to predict 5-year risk, since clinical trials 
are often performed over 5 years, and some variables may dispro-
portionately predict more proximate episodes of pneumonia. 
 We compared the clinical usefulness of the risk prediction model 
and the Centers for Disease Control and Prevention (CDC) guide-
lines for pneumococcal vaccination by comparing the proportion 
of the population who would have to be treated and the propor-
tion of pneumonia cases that would be identifi ed using different 
thresholds of the clinical risk prediction model and for the CDC 
guidelines. 7,34 Finally, we assessed incremental benefi t of adding 
biomarkers to the clinical risk prediction model by estimating 
improvement in AUC and calculating NRI and integrated discrimi-
nation improvement (IDI). 33 
 Results 
 Baseline characteristics of the three individual cohorts 
and the derivation (n  5 16,260), internal validation 
(n  5 5,420), and external validation (n  5 3,075) cohorts 
are described in  Table 1 and e-Appendix 1. The der-
ivation cohort included 24% black participants, and 
the age distribution was similar to the age distribution 
of the US population   45 years old in 1990, with slightly 
fewer older individuals (e-Table 1). Thus, the deriva-
tion cohort was fairly representative of community-
dwelling individuals from the US population. Most 
clinical characteristics were virtually identical in the 
derivation and internal validation cohorts. The preva-
lence of chronic kidney disease, as evidenced by glo-
merular fi ltration rate  , 60 mL/min/1.73 m 2 , was lower 
in the derivation and internal validation cohorts com-
pared with the external validation cohorts (7.3% vs 
13.31%). 
 Incidence and Mortality 
 Of the 16,260 participants, 1,000 participants (6.15%) 
were hospitalized with pneumonia at least once over 
10 years. Of these, most were hospitalized for bacterial 
pneumonia (n  5 660). The median time to hospitalization 
was 5.95 years (interquartile range  5 3.48-8.19 years). 
The crude and age-adjusted incidences were 6.71 and 
9.43 cases/1,000 person-years. The 30-day and 1-year 
mortality after pneumonia were 16.5% and 31.5%. 
Even subjects hospitalized with bacterial pneumonia, 
for whom an ICD-9 code for pneumonia was recorded 
as the primary diagnosis code, had high 30-day case 
fatality and 1-year mortality (12.12% and 26.67%). 
 Risk Factors 
 Univariate analyses with RR, AUC, and missing data 
for individual risk factors are shown in  Table 2 . Age was 
an important risk factor, and the average age of develop-
ing pneumonia was 75 years (SD  5 10 years). Age was 
associated with increased risk ( Fig 1 ). Although most 
pneumonia cases (62%) occurred among those  . 65 years 
of age, 38% occurred among those 45 to 65 years old 
( Fig 1 ). The 30-day and 1-year mortality for those 45 to 
65 years old were 12.5% and 25.7%. The 1-year mor-
tality after pneumonia hospitalization remained high 
among younger participants, when we excluded those 
with a chronic health condition (14.29%) and addi-
tionally excluded those who ever smoked (12.82%). 
 Severe reduction in lung function, as evidenced by 
percent predicted FEV 1  , 50%, increased the risk of 
CAP 6.61-fold (95% CI  5 5.25-8.32) compared with 
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those with FEV 1   80%. A modest increase in risk 
was observed for those with mild or moderate reduction 
in lung function (percent predicted FEV 1 , 50%-80%; 
RR  5 2.38; 95% CI  5 2.05-2.76) and other chronic 
health conditions. Smoking was also associated with 
a higher risk (RR and 95% CI were 1.61 [1.37-1.90] 
and 1.40 [1.21-1.63]) for current smokers and past 
smokers compared with never smokers). 
 Development and Validation of Clinical Risk 
Prediction Model 
 Age had the highest AUC (AUC  5 0.74); the AUC 
for reduced lung function was 0.65, whereas other 
chronic diseases, race, sex, and smoking had AUC 
values near 0.5 ( Table 2 ). The sequential addition of 
FEV 1 and smoking to age had the highest improve-
ment in NRI ( Table 3 ), and small improvement in 
AUC and NRI occurred when additional variables 
were added. Thus, the fi nal clinical risk prediction 
model included age, % predicted FEV 1 , and smoking 
( Table 4 ). Interactions of all age groups with smoking 
and FEV 1 were assessed and were signifi cant for those 
70 to 85 years of age ( Table 4 ). The risk prediction 
model had moderate discrimination and excellent cali-
bration (AUC  5 0.77; 95% CI, 0.76-0.79; HL C sta-
tistic, 0.12) ( Fig 2 ). Model discrimination was similar 
in the internal validation cohort (AUC  5 0.77; HL C 
statistic, 0.65). Model discrimination was lower in 
external validation cohort (AUC  5 0.62), but calibra-
tion was excellent (HL C statistic, 0.45) ( Fig 2 ). 
 Sensitivity Analyses 
 The estimates remained unchanged using the more 
specifi c defi nition for hospitalization for bacterial pneu-
monia and using Cox proportional hazards model to pre-
dict risk of hospitalization with pneumonia (e-Table 2). 
Model calibration was good among black participants 
(HL C statistics in derivation and internal and exter-
nal validation cohorts  5 0.51, 0.38, and 0.78), among 
younger participants (HL C statistics in derivation 
and internal validation cohorts  5 0.13 and 0.99), and 
the clinical prediction model calibrated well to pre-
dict 5-year risk of pneumonia (HL C statistic in deri-
vation cohort  5 0.26). 
 Infl ammatory Biomarkers 
 See e-Appendix 1 for details. In all three cohorts, 
baseline CRP was associated with higher risk of pneu-
monia hospitalization (ORs with 95% CIs per SD 
 Table 1— Clinical Characteristics of Various Cohorts at Enrollment 
Variables 
ARIC 
(n  5 15,792)
CHS 
(n  5 5,888)
Health ABC 
(n  5 3,075)
Combined ARIC and CHS
Derivation Cohort 
(n  5 16,260)
Internal Validation 
(n  5 5,420)
Demographics
 Age at enrollment, mean (SD) 54.16 (5.76) 72.35 (5.42) 73.62 (2.87) 59.23 (10.06) 59.24 (10.19)
 Age at hospitalization for 
  pneumonia, mean (SD), y
70.12 (6.35) 82.44 (6.00) 78.97 (3.74) 75.08 (10.36) 74.97 (10.43)
 Sex, female (%) 8,710 (55.15) 3,393 (57.63) 1,584 (51.51) 9,088 (55.89) 3,015 (55.63)
 Race, black (%) 4,266 (27.01) 924 (15.69) 1,281 (41.66) 3,896 (24.01) 1,294 (23.94)
Common risk factors for pneumonia 
  at enrollment
 Smoking
  Current 4,132 (26.16) 700 (11.90) 318 (10.36) 3,577 (22.02) 1,255 (23.18)
  Former 5,972 (32.15) 2,444 (41.55) 1,404 (45.73) 5,622 (34.61) 1,894 (34.98)
  Never 6,572 (41.66) 2,738 (46.55) 1,348 (43.91) 7,045 (43.37) 2,265 (41.84)
 Pack-y of smoking, 
  mean (SD, median)
16.06 (21.84) 18.43 (27.17) 19.06 (28.00) 16.48 (23.04) 17.13 (23.98)
 BMI, kg/m 2 27.71 (5.37) 26.88 (4.77) 27.39 (4.82) 27.40 (5.21) 27.35 (5.19)
 Heart failure (%) 752 (4.85) 275 (4.67) 95 (3.11) 766 (4.77) 261 (4.89)
 Coronary heart disease (%) 766 (4.96) 1,154 (19.60) 625 (20.81) 1,418 (8.86) 502 (9.43)
 Diabetes (%) 1,870 (11.95) 1,493 (28.89) 468 (15.28) 1,109 (7.11) 384 (7.37)
 Chronic kidney disease a (%) 598 (5.11) 764 (13.24) 683 (22.21) 1,169 (7.30) 193 (13.31)
Lung function using FEV 1 
 % predicted FEV 1 , mean (SD) 93.27 (17.42) 90.00 (22.26) 94.08 (21.89) 92.53 (18.81) 92.07 (18.98)
 % predicted FEV 1 
  , 50% 307 (1.96) 322 (5.80) 93 (3.25) 476 (2.99) 153 (2.88)
 50%-80% 2,697 (17.22) 1,252 (22.54) 595 (20.78) 2,907 (18.28) 1,042 (19.61)
  . 80% 12,654 (80.81) 3,980 (71.66) 2,175 (75.97) 12,516 (78.72) 4,118 (77.51)
All variables measured at baseline (study entry). ARIC  5 Atherosclerosis Risk in Communities; CHS  5 Cardiovascular Health Study; GFR  5 
glomerular fi ltration rate; Health ABC  5 Health, Aging, and Body Composition.
 a Based on estimated GFR using Modifi cation of Diet in Renal Disease study equation. Chronic kidney disease defi ned as GFR  , 60 mL/min/1.73 m 2 .
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increase in CRP for ARIC, CHS, and Health ABC were 
1.21 [1.15-1.28], 1.08 [1.02-1.15], and 1.12 [1.02-1.21], 
respectively, and  P values were  , .0001,  , .0001, and 
.04, respectively). However, the addition of CRP to 
the clinical model resulted in a small improvement 
in model discrimination. For example, in ARIC, the 
AUC improved from 0.67 to 0.69, 5.7% of cases were 
reclassifi ed ( P  5 .02) (e-Table 3), and IDI was 0.5% 
( P  , .0001). In CHS, there was no improvement in 
the AUC, no improvement in NRI, and very small 
improvement in IDI (0.1%,  P  5 .03) (e-Table 4). In 
Health ABC, the addition of CRP to the clinical risk 




Pneumonia (n  5 1,000)
Never Hospitalized for 
Pneumonia a (n  5 15,260) RR (95% CI) AUC Missing, %
Demographics
 Age at enrollment in the study, 
 mean (SD), y
67.92 (10.65) 58.67 (9.75) … b 0.74 0
 Sex, female (%) 496 (49.60) 8,592 (56.30) 1.31 (1.15-1.49) 0.53 0
 Race, black (%) 202 (20.24) 3,694 (24.26) 0.85 (0.73-0.99) 0.51 0.2
Alcohol abuse (%) 90 (9.08) 1422(9.38) 0.97 (0.77-1.21) 0.50 0.6
Smoking, current/former/never (%) 27.50/38.00/34.50 21.66/34.39/43.95 1.61 (1.37-1.90) c 0.55 0.1
1.40 (1.21-1.63) d 
Pack-y of smoking, mean (SD) 24.71 (29.12) 15.85 (22.52) 1.01 (1.01-1.02) 0.58 2.1
BMI, kg/m 2 ( , 18.5 and  . 25 vs 18.5-25) 26.55 (5.08) 27.46 (5.21) 1.96 (1.29-2.97) 0.54 3.4
0.84 (0.74-0.97)
Heart failure (%) 91 (9.17) 675 (4.48) 2.15 (1.71-2.70) 0.52 1.2
Coronary heart disease (%) 202 (20.38) 1216 (8.09) 2.90 (2.46-3.42) 0.56 1.5
Diabetes (%) 620 (67.17) 4,668 (31.82) 2.03 (1.76-2.35) 0.53 4.1
Chronic kidney disease e (%) 145 (14.83) 1,024 (6.81) 2.38 (1.97-2.87) 0.54 1.5
Lung function
 % predicted FEV 1 , mean (SD) 81.49 (23.86) 93.22 (18.24) … b 0.65 2.2
 FEV1, % predicted  , 50, 50-80 vs  . 80 11.73/30.28/58.00 2.45/17.53/80.02 6.61 (5.25-8.32) 0.62 …
2.38 (2.05-2.76)
AUC  5 area under curve; RR  5 relative risk. See Table 1 legend for expansion of other abbreviations.
 a P values for all comparisons were  , .0001, except for race, where  P  5 .04.
 b Incidence rates for different age groups described in text.
 c RR for current vs never smokers.
 d RR for former vs never smokers.
 e Based on estimated GFR using Modifi cation of Diet in Renal Disease Study equation. Chronic kidney disease defi ned as GFR  , 60 mL/min/1.73 m 2 .
  
 Figure 1. Proportion of pneumonia cases and crude incidence rates across different age groups . 
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prediction model did not improve AUC (e-Table 5). 
Similarly, IL-6 was also associated with a higher risk 
of pneumonia hospitalization (OR per SD increase 
in IL-6 was 1.16 [1.06-1.28],  P  5 .002), but did not 
improve performance of the clinical risk prediction 
model (e-Appendix 1, e-Table 6). 
 Clinical Application of Prediction Model 
 We developed a simplifi ed decision rule to catego-
rize participants into different risk categories based 
on hierarchical application of the identifi ed risk fac-
tors (e-Appendix 1, e-Fig 1). We also determined the 
clinical application of the model in the external vali-
dation cohort by estimating the number of pneumonia 
cases identifi ed using different risk cutoffs ( Fig 3 ). 
Most subjects had a predicted risk  . 5%, and since all 
participants in the external validation cohort were 
 . 65 years of age, the CDC guidelines for pneumococcal 
vaccination would require targeting all subjects for 
prevention. Targeting those with predicted risk  . 5%, 
 . 10%, and  . 15% predicted risk would target 90.4%, 
39.1%, and 14.4% of the subjects in this cohort and 
identify 88.9%, 55.1%, and 26.8% of pneumonia cases, 
respectively. To illustrate a strategy of targeting a more 
select population, such as those with risks of   10% 
in the clinical risk prediction model, would require 
treating approximately one-third of the population 
and identify one-half of pneumonia cases. Targeting 
only high-risk participants (  15% risk) or 14% of the 
population would identify one-fourth of pneumonia 
cases, a subgroup that could be targeted initially to 
conduct randomized clinical trials to test pharmaco-
logic interventions cost-effectively. 
 Similar analyses to test targeted strategies were con-
ducted in the derivation cohort (e-Fig 2A). Finally, the 
clinical risk prediction model was also particularly likely 
to identify fatal pneumonia cases, as evidenced by 
higher 30-day and 1-year mortality for participants with 
higher predicted risk (e-Fig 2B). 
 Table 3— AUC and NRI for Different Combination of 
Variables to Develop the Risk Prediction Model 
Variable AUC NRI a 
Age 0.74 …
 With % predicted FEV 1 0.76 15.01
 With smoking 0.76 12.40
 With heart failure 0.75 4.60
 With diabetes 0.74 3.10
 With coronary heart disease 0.74 5.70
 With sex 0.74 2.20
 With race 0.74  , 0.01
 With BMI 0.74 1.50
 With chronic kidney disease 0.74 0
Age and % predicted FEV 1 0.76 …
 With smoking 0.77 6.14
 With heart failure 0.77 3.70
 With diabetes 0.77 2.0
 With coronary heart disease 0.77 0.90
 With sex 0.77 1.50
 With race 0.76 1.90
 With BMI 0.77 0.09
 With chronic kidney disease 0.77  2 0.01
Age and smoking 0.76 …
 With % predicted FEV 1 0.77 9.90
 With heart failure 0.76 1.40
 With diabetes 0.77 0.97
 With coronary heart disease 0.76 0.67
 With sex 0.76  2 0.85
 With race 0.76  2 0.76
 With BMI 0.76  2 0.16
 With chronic kidney disease 0.76  2 0.007
Age, % predicted FEV 1 , and smoking 0.77 …
 With heart failure 0.77 2.60
 With diabetes 0.78 2.30
 With coronary heart disease 0.77 2.0
NRI  5 net reclassifi cation improvement. See Table 1 legend for expan-
sion of other abbreviation.
 a NRI is calculated as described by Pencina et al. 33 Briefl y, it is calculated 
as follows: NRI  5 [P(up|D  5 1)  2 P(down|D  5 1)]  2 [P(up|D  5 0)  2 
P(down|D  5 0)], where Pup and Pdown are the probabilities of par-
ticipants reclassifi ed to a higher and lower risk category and D  5 0 
and D  5 1 indicate groups in which pneumonia did and did not occur.




RR (95% CI)  P Value
Age, y
  , 50 … …
 50-55 1.43 (0.99-2.05) .05
 55-60 2.20 (1.57-3.08)  , .0001
 60-65 2.66 (1.91-3.72)  , .0001
 65-70 4.81 (3.43-6.75)  , .0001
 70-75 9.93 (7.00-14.08)  , .0001
 75-80 14.72 (10.17-21.31)  , .0001
 80-85 27.87 (18.67-41.58)  , .0001
  . 85 16.13 (9.73-26.76)  , .0001
Lung function
 Predicted FEV 1  . 80% … …
 Predicted FEV 1 50%-80% 2.14 (1.75-2.62)  , .0001
 Predicted FEV 1  , 50% 5.73 (4.22-7.79)  , .0001
Smoking
 Never smoker … …
 Past smoker 1.26 (1.07-1.49) .005
 Current smoker 2.06 (1.70-2.50)  , .0001
Logit(p)  5  2 4.5885  1 0.7597*(if PPFEV 1 : 50%-80%)  1 1.7462*(if 
PPFEV 1 :  , 50%)  1 0.3552 (if Age: 50-55 y)  1 0.7885 (if Age: 55-60 y)  1 
0.9792 (if Age: 60-65 y)  1 1.5714 (if Age: 65-70 y)  1 2.2951 (if 
Age: 70-75 y)  1 2.6892 (if Age: 75-80 y)  1 3.3274 (if Age: 80-85 y)  1 
2.7808 (if Age:  . 85 y)  1 0.2338 (if Previous Smoker)  1 0.7240 (if 
Current Smoker)  1  2 0.2977*(if PPFEV 1 : 50%-80% and Age: 70-75 y)  1 
 2 0.8383*(if PPFEV 1 :  , 50% and Age: 70-75 y)  1  2 0.3415*(if PPFEV 1 : 
50%-80% and Age: 75-80 y)  1  2 1.1867*(if PPFEV 1  , 50% and Age: 
75-80 y)  1  2 0.9957*(if PPFEV 1 : 50%-80% and Age: 80-85 y)  1 
2 1.3284*(if PPFEV 1  , 50% and Age: 80-85 y). Predicted risk of 
community-acquired pneumonia  5 1/1  1 e-logit(p). PPFEV 1  5 percent 
predicted FEV 1 . See Table 2 legend for expansion of other abbreviation.
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 Discussion 
 Our results showed that hospitalization with pneu-
monia is common, even in younger adults. More than 
one-third of all pneumonia cases occurred in those 
younger than 65 years, and the short- and long-term 
mortality remained high in these individuals. Long-term 
risk of pneumonia hospitalization can be predicted in 
community-dwelling well-functioning adults using a 
simple clinical risk prediction model based on age, 
smok ing status, and lung function. Circulating CRP and 
IL-6 levels do not materially improve discrimination. 
 Perhaps strikingly, the incidence of pneumonia 
requiring hospitalization was similar or higher than 
the incidence of acute myocardial infarction or stroke in 
the general population. 35,36 In contrast to the incidence 
of acute myocardial infarction (2.74 cases/1,000 person-
years), the incidence of pneumonia hospitalization 
was 2.5-fold higher (6.71 cases/1,000 person-years), 
and these estimates are similar to results of prior studies 
using administrative data. 13,27 Compared with cardio-
vascular disease, the short- and long-term mortality 
after pneumonia was high. Even in younger adults, 
the 1-year mortality after pneumonia was 12.82% among 
those without a major chronic health condition and 
those who never smoked, a subgroup in whom mor-
tality can be attributed to pneumonia rather than under-
lying chronic disease. Furthermore, the higher mortality 
was also observed in cases in which pneumonia was 
the primary reason for hospitalization and unlikely to 
be explained by inclusion of subjects with hospital-
acquired pneumonia. Thus, pneumonia is a major public 
  
 Figure 2. Model discrimination (using AUC) and calibration (using HL C statistic) for the pneumonia 
clinical risk prediction model in the derivation, internal validation, and external validation cohorts. 
AUC  5 area under curve; HL  5 Hosmer-Lemeshow. 
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health problem, and designing new preventive strat-
egies to reduce risk of pneumonia is important. 
 We developed and validated a simple risk predic-
tion model that could be used to identify different 
risk groups and target expensive preventive strategies 
that have adverse events. In contrast to the CDC 
guidelines for pneumococcal vaccine, which target a 
broad population based on age and presence of any 
chronic disease, our risk prediction model offers a 
better opportunity to evaluate the balance between 
the threshold of risk chosen and the number of indi-
viduals at risk (e-Fig 1). For example, one would have 
to recruit 3,500 high-risk subjects and follow them 
over 5 years to test a preventive intervention that would 
reduce risk of pneumonia by 25%. If this intervention 
is effective, then our prediction model could be used to 
target this intervention, especially in younger adults. 
 Our study has several strengths. First, CHS and 
ARIC cohorts included probability-based samples of 
community-dwelling well-functioning individuals from 
seven US states. The distribution of participants was 
fairly similar to the US population, and one-fourth of 
participants were black. Second, we had objective 
assessment of the burden and severity of chronic dis-
eases rather than relying on self-report. Third, we 
assessed long-term risk of pneumonia over 10 years, 
much longer than most studies have done. Finally, we 
examined the role of biomarkers to predict risk of pneu-
monia. Although associated with higher risk, infl am-
matory biomarkers did not improve performance of 
our clinical risk prediction model. 
 Our study has limitations. First, CAP is a clinical 
syndrome diagnosed based on clinical symptoms and 
radiographic fi ndings, and microbiologic confi rmation 
is usually available in fewer than one-third of cases in 
routine clinical practice. 37 We used ICD-9 codes shown 
to have good sensitivity and specifi city in prior studies 
and validated these codes in our study. 27,28 We used 
two criteria, a sensitive criterion for CAP based on 
ICD-9 codes in fi rst fi ve discharge diagnoses fi elds 
and a more specifi c criterion using ICD-9 codes for 
bacterial pneumonia in the fi rst discharge diagnosis 
fi eld. About two-thirds of all hospitalizations with pneu-
monia met the latter criteria, and in two-thirds of the 
remainder, pneumonia was the primary reason for 
hospitalization. Thus, few pneumonia cases in our 
derivation cohort are likely to be hospital acquired. 
The relative risks for the risk prediction model were 
similar using both criteria, suggesting that misclassifi -
cation of cases is unlikely to affect our results. Fur-
thermore, the model was validated in Health ABC, in 
which physicians conducted chart review to confi rm 
all cases of hospitalized pneumonia. 
 Second, we focused on hospitalization for pneu-
monia in this study and did not include nonhospital-
ized cases. We did so in part because chest radiographs 
are not routinely obtained in outpatient settings, and 
it is diffi cult to distinguish between bronchitis and 
pneumonia. Outpatient pneumonia cases also have 
lower mortality and may, therefore, be less impor-
tant to prevent. However, due to exclusion of these 
cases we may have overestimated the effect of age, as 
younger individuals with pneumonia are less likely to 
be hospitalized. 
 Third, we assessed the role of baseline character-
istics to develop the risk prediction model. Future stud-
ies should include repeated measures of potential 
predictors to determine whether these risk factors 
may be associated with pneumonia susceptibility in 
shorter time frames. Finally, the three cohorts had 
  
 Figure 3. Proportion of pneumonia cases and the proportion of population that would have to be tar-
geted using different thresholds of the clinical risk prediction model in the external validation cohort. To 
illustrate a strategy of targeting a more select population, such as those with risks of  . 10%, would 
require treating approximately one-third of the population and identify one-half of pneumonia cases. 
Targeting only high-risk participants ( . 15% risk) or 14% of the population would identify one-fourth of 
pneumonia cases, a subgroup that could be targeted initially to conduct randomized clinical trials to test 
pharmacologic interventions cost-effectively. 
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very few Hispanics, and whether our risk prediction 
model can be generalized to this ethnic group remains 
unknown. 
 In conclusion, pneumonia is common across a wide 
spectrum of age and associated with high short- and 
long-term mortality even in younger adults. Using the 
key risk factors of age, smoking, and lung function, 
the risk of pneumonia hospitalization can be predicted 
using a simple clinical risk prediction model. In the 
future, this model can be used to design clinical trials 
to test new preventive strategies for pneumonia and 
target proven prevention efforts to those at highest 
risk of this condition. 
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